A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation ...

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has developed a promising new therapeutic strategy for fibrodysplasia ossificans ...

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...

Sept 17 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Wednesday its experimental treatment for a rare genetic disorder affecting soft tissue significantly reduced abnormal bone ...

Bone Loss Lessened by Blocking Abnormal Stem Cell Signal September 28, 2023 A new study in mice led by researchers from NYU Grossman School of Medicine found that blocking the signaling pathway, ...

Osteogenesis imperfecta (OI) refers to a group of rare genetic bone disorders that results in the formation of fragile bones. In patients with OI, the matrix that makes up the bone has been found to ...

The condition called idiopathic osteoporosis (IOP) occurs in younger adults and often involves bone fractures, even in patients with no history of physical trauma. Head of Hudson Institute’s Metabolic ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...